Tevogen bio highlights the future of ai-driven drug development in fireside chat with microsoft during the j.p. morgan healthcare conference

Warren, n.j., jan. 23, 2025 (globe newswire) -- tevogen bio holdings inc. (“company” or “tevogen bio”) (nasdaq: tvgn ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified t-cell therapeutics for infectious diseases and cancers, today announced key insights from its recent fireside chat during the j.p. morgan healthcare conference. utilizing artificial intelligence (ai) and machine learning (ml) has been critical for tevogen bio, given its core commitment to patient equity. by applying ml through tevogen.ai, the company has already achieved notable cost and time efficiencies, developments that could translate directly into savings for patients. the discussion featured dr. david rhew, global chief medical officer & vp of healthcare at microsoft (nasdaq: msft), and mittul mehta, chief information officer and head of tevogen.ai, who shared their vision for how ai is revolutionizing drug development and healthcare delivery.
MSFT Ratings Summary
Quant
MSFT Quant Ranking
Sector
Industry
Quant Rating
Quant Score